

AUG. 31. 2004 11:40AM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 6953 P. 2

PATENT

AUG 31 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MICHAELIS, et al.

Examiner:

Art Unit: 1646

Application No.: 10/773,772

Filed: 6 February 2004

Title: **THE USE OF ANTAGONISTS OF THE
BRADYKININ B2 RECEPTOR FOR THE
TREATMENT OF OSTEOARTHRISIS**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,
at (703) 746-9195, on

August 31, 2004

Date of Transmission

Signature

REQUEST FOR CORRECTED FILING RECEIPT


Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the title that should read "THE USE OF ANTAGONISTS OF THE
BRADYKININ B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHRISIS" as shown on the
enclosed copy of the Application Data Sheet, not "THE USE OF ANTAGONISTS OF THE BRADYKININ
B2 RECEPTOR FOR THE TREATMENT OF OSTEOARTHRISIS".

The error on the Filing Receipt is not due to the Applicant; therefore, no additional fees should be
required, however the Commissioner is hereby authorized to charge any fees which are required by
this paper to Deposit Account 18-1982.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065
Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0008 US NP



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1430
Alexandria, Virginia 22313-1430
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/773,772	02/06/2004	1646	770	DEAV2003/0008USNP		7	1

CONFIRMATION NO. 7891

05487

ROSS J. OEHLER
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807

FILING RECEIPT

OC000000012584500

COMPUTER ENTERED

5/11/04

Date Mailed: 05/11/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-8195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Martin Michaelis, Frankfurt, GERMANY;
Karl Rudolphi, Mainz, GERMANY;

Assignment For Published Patent Application

Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/480,246 06/20/2003

Foreign Applications

GERMANY DE10304994.0-41 02/07/2003

If Required, Foreign Filing License Granted: 05/10/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthritis

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).